apparently the market has some concerns about it. INCY's Jakafi is already on the market, but this happened to ICPT when GILD bought a NASH player? ICPT is ahead in its trials, but the power of GILD is just intimidating. INCY also has baricitinib, with Lilly, which is off to the races. I think the negative stock move is more about the idea that GILD won't buy INCY, as people had been speculating, although GILD might still like INCY's oncology portfolio.